Q1 2025 Management View CEO Phillip Chan reported that CytoSorbents is focused on three main areas: the performance and growth catalysts of the core CytoSorb business, regulatory status and plans for ...

Discover key takeaways from Talphera's Q1 2025 Earnings Call! Learn about FDA protocol changes, financial updates, and progress on the NEPHRO CRRT study.

BioCardia, Inc. ( NASDAQ: BCDA) Q1 2025 Earnings Conference Call May 14, 2025, 16:30 PM ET Peter Altman - President and CEO David McClung - CFO Miranda Peto - IR Joe Pantginis - H.C. Wainwright Laura ...

The latest health news highlights Sanofi's $20 billion U.S. investment through 2030, Merck's cancer drug expansion and the ...

Received a "Study May Proceed” letter from the FDA for the Phase 2 trial for the treatment of FAP. This trial, run by CP-CTNet and financially supported by the NCI's Division of Cancer Prevention, ...

The Justice Department plans to bolster enforcement and deportation work in 25 cities across the United States.

Although these factors will affect Omron's free cash flow generation in fiscal 2024, we expect this to be temporary and the company's financial health to return to its normal state over the medium ...

Information technology and pharma sector, Tata Steel Ltd., and Hindalco Ltd. were among the top companies on brokerages' ...

A successful M&A outcome is contingent upon a deep understanding of the regulatory and scientific fundamentals that underpin ...

Recently, underscoring a commitment to national security, the White House and the Food and Drug Administration (FDA) issued separate ...

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of ...

The API is, one might say, the most important element in a pharmaceutical product. Poor-quality APIs that do not meet potency ...